Platelets and Regulatory T Cells May Induce a Type 2 Immunity That Is Conducive to the Progression and Fibrogenesis of Endometriosis

Fengyi Xiao\textsuperscript{1†}, Xishi Liu\textsuperscript{1,2†} and Sun-Wei Guo\textsuperscript{1,2*}

\textsuperscript{1} Shanghai OB/GYN Hospital, Fudan University, Shanghai, China, \textsuperscript{2} Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Fudan University, Shanghai, China

Endometriosis is a hormonal disease, as well as a chronic inflammatory disease. While various immune cells are documented to be involved in endometriosis, there is a wanton lack of a bigger picture on how these cells are coordinated to work concertedly. Since endometriotic lesions experience cyclical bleeding, they are fundamentally wounds that undergo repeated tissue injury and repair (ReTIAR). In this study, we attempted to characterize the role of platelets and regulatory T cells (Tregs) in modulating the lesional immune microenvironment and its subsequent effects on lesional progression and fibrogenesis. Through two mouse experiments, we show that, by disrupting predominantly a type 2 immune response in lesional microenvironment, both platelets and Tregs depletion decelerated lesional progression and fibrogenesis, likely through the suppression of the TGF-\(\beta\)/Smad3 and PDGFR-\(\beta\)/PI3K/Akt signaling pathways. In particular, platelet depletion resulted in significantly reduced lesional expression of thymic stromal lymphopoietin (TSLP), leading to reduced aggregation of macrophages and alternatively activated (M2) macrophages, and of Tregs, T helper 2 (Th2) and Th17 cells but increased aggregation of Th1 cells, in lesions, which, in turn, yields retarded fibrogenesis. Similarly, Tregs depletion resulted in suppression of platelet aggregation, and reduced aggregation of M2 macrophages, Th2 and Th17 cells but increased aggregation of Th1 cells, in lesions. Thus, both platelet and Tregs depletion decelerated lesional progression and fibrogenesis by disrupting predominantly a type 2 immunity in lesional microenvironment. Taken together, this suggests that both platelets and Tregs may induce a type 2 immunity in lesional microenvironment that is conducive to lesional progression and fibrogenesis.

Keywords: endometriosis, platelet, regulatory T cell, type 2 immunity, macrophage, fibrosis
INTRODUCTION

Featuring the presence of endometrial tissue outside of the uterine cavity and often characterized by pelvic pain and subfertility or infertility, endometriosis is a common gynecological disease affecting women of reproductive age (1). Evidence accrued in the last few years indicates that, like eutopic endometrium, endometriotic lesions undergo cyclical bleeding and the ensuing tissue repair, and thus akin to wounds undergoing repeated tissue injury and repair (ReTIAR), leading ultimately to fibrosis through epithelial-mesenchymal transition (EMT), fibroblast-to-myofibroblast transdifferentiation (FMT), and smooth muscle metaplasia (SMM) (2–4). Along with the ReTIAR line, we have previously shown that platelets are critically involved in the development of endometriosis (3, 5–7). We also have shown that M2a macrophages are involved in the fibrogenesis of endometriosis (8). Through the looking glass of this ReTIAR, we can readily understand why deep endometriosis is more fibrotic than ovarian endometrioma and why lesions are resistant to medical treatment (9), and why many drugs that shined in preclinical studies but failed in clinical trials (10). The ReTIAR notion also helps to shed new light on the pathophysiology of endometriosis (11), and help devise novel diagnostics of endometriosis (12).

Tissue repair following injury is of vital importance to the survival of all living organisms. Tissue repair can be roughly divided into several distinct but somehow overlapping phases: hemostasis, inflammation, proliferation, and remodeling (13). In all phases, immune cells are actively involved. Platelets and macrophages belong to the innate immune system, but the role of adaptive immunity in the progression of endometriosis is not well understood. To counter the deleterious effect of inflammation, specialized subsets of lymphocytes are recruited into the wounding sites to avoid tissue damage inflicted by excessive inflammation (14). Of particular interest is the forkhead box protein 3 (FOXP3) positive regulatory T cells (Tregs), which are known to play an indispensable role in establishing and maintaining immunosuppression as well as tissue homeostasis (15). More importantly, it has been established that Tregs are involved in eliciting type 2 immunity that is implicated in various fibrotic disorders (16) and are very likely to be involved in fibrogenesis of endometriosis as well.

Type 2 immunity is characterized by the production of interleukin (IL)-4, IL-5, IL-9, IL-13, IL-25, and IL-33, as opposed to type 1 immunity, which features interferon γ (IFNγ), IL-2, tumor necrosis factor α (TNF-α), and IL-12 cytokines (16). Key cell types associated with type 2 immune responses, including T helper 2 (Th2) cells, eosinophils, mast cells, basophils, type 2 innate lymphoid cells (ILC2s), and IL-4- and IL-13-activated macrophages (M2), regulate tissue repair following injury. Nevertheless, when the type 2 cytokine-mediated repair process goes awry, they can also contribute to the development of pathological fibrosis in many different organs/tissues (16).

In endometriosis, there seem to be conflicting reports on the Th1/Th2 response (17–19), but a preponderance of data indicate that a Th2 immune response appears to be more predominant (18, 20, 21). Indeed, Th2 cytokines, or more generally, a type 2 immunity, is typically regarded as anti-inflammatory and reparative in tissue repair, and, when dysregulated, drives fibrogenesis (16). IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) have been identified to be key initiators of this type 2 immunity (22). In particular, TSLP is viewed as a master switch in inducing type 2 immune response (23, 24).

TSLP belongs to the IL-2 cytokine family and is structurally related to IL-7 (25). TSLP promotes the differentiation of naïve T-cells into a Th2 phenotype and the secretion of various profibrotic factors, including IL-13 (26). Following injury, epithelial cell-derived TSLP activates local dendritic cells (DCs) to secrete CC chemokine ligand 22 (CCL22) and CCL17, promoting Th2 cell differentiation and propagating the type 2 immune response (16). Activated platelets can induce TSLP production by microvascular endothelial cells in an IL-1β dependent manner (27). Macrophages also can secrete TSLP to promote pulmonary fibrosis (28). In endometriosis, TSLP is expressed in both stromal and epithelial cells, and its concentration in serum and peritoneal fluid from women with endometriosis has been reported to be elevated (29). Both IL-1β and estrogen can stimulate the TSLP production in endometriotic stromal cells (29, 30).

Human platelets express functional TSLP receptors, which can be activated by TSLP to promote platelet activation (31). TSLP influences Tregs differentiation and development (32), and stimulates the proliferation of FOXP3+ Tregs in the peripheral tissues and thymus (33).

Viewed from the ReTIAR vista, it is only natural to speculate that a type 2 immune response should prevail in lesional microenvironment as endometriosis progresses. Precisely due to the progressive nature, it is imperative to investigate this possibility in a serially designed experiment, which can be feasible only in an animal study. We started from the perturbation by depleting platelets, which are shown to play a critical role in lesional development (3, 5, 34). Due to the important role that Tregs play in type 2 immunity, we also perturbed the lesional progression by depleting Tregs with and without platelet depletion. We hypothesized that platelet and/or Tregs depletion would disrupt the type 2 immune response in lesional progression, stalling lesional fibrogenesis. This study was undertaken to test this hypothesis.

MATERIALS AND METHODS

Animals

A total of 120 7-week-old virgin female Balb/C mice were purchased from the SLAC Experimental Animal Company (Shanghai, China) and used for this study. All mice were maintained under controlled conditions with a cycle of 12:12 h light/dark and had access to food and water ad libitum.

All experiments were performed under the guidelines of the National Research Council’s Guide for the Care and Use of Laboratory Animals (35) and were approved by the Institutional Experimental Animals Review Board of Shanghai OB/GYN Hospital, Fudan University.
Induction of Endometriosis

We used an established mouse model of endometriosis by induction through intraperitoneal injection of uterine fragments (36), which has been used in our previous studies (5). In brief, after 1 week of acclimatization, 7-week-old donor mice were initially injected with 100 μg/kg estradiol benzoate (Animal Medicine Factory, Hangzhou, China) intramuscularly, twice a week. One week later they were sacrificed and their uteri were harvested. The uterine tissues were seeded in a Petri dish containing warm sterile saline and divided longitudinally with scissors. Two uterine horns from each mouse were minced with scissors to make sure that the maximal diameter of the fragments was consistently smaller than 1 mm. Then the fragments were injected intraperitoneally to recipient mice. To eliminate potential bias, endometrial fragments from one or two donor mice were mixed and injected intraperitoneally to two or four mice, each from one of the two or four groups. The animals were sacrificed 5 weeks after induction.

Mouse Experiment Protocol

For Experiment 1, 48 mice were randomly divided into two equal-sized groups: the isotype control (IC) group and the platelet depletion (PD) group. For platelet depletion, mice were injected intravenously with an anti-platelet antibody (R300, Emfret Analytics, Eibelstadt, Germany), and for the IC group, the mock isotype antibody matched with anti-platelet antibody (rat IgG1) (C301, Emfret Analytics), both at a dosage of 2 μg/g bodyweight for each injection. For both groups, the real or mock antibody was injected at the day of induction of endometriosis (day 0), and then 3 days consecutively, with the last injection being given on day 30. The schematic depiction of the experimental design is shown in Figure 1A. As reported previously by our group, the average platelet count in mice injected with the identical anti-platelet antibody (R300) at a 3-day interval was 15 × 10⁹/L in the blood, while those injected with the matched IC had an average platelet count of 136 × 10⁹/L. That is, the platelet count was reduced by 89.0% (5). At the end of the first and second weeks after induction of endometriosis, seven mice each were sacrificed; at the end of the fifth week after induction, 10 mice each were sacrificed. Before the induction of endometriosis and before sacrifice, the body weight was measured and the hotplate latency test was administered to all mice.

For Experiment 2, 32 mice were randomly divided into four equal-sized groups: the Control (CT) group, the platelet depletion (PD) group, the Tregs depletion (TD) group, and the joint platelet and Tregs depletion (JD) group. For PD mice, mice were injected intravenously with an anti-platelet antibody or the mock isotype antibody mentioned above (both from Emfret Analytics), at a dosage of 2 μg/g bodyweight for each injection, and at seven different time points for the four groups. For PD mice, mice were injected intraperitoneally with monoclonal anti-CD25 antibody (PC61) or the mock isotype antibody matched with PC61 (rat IgG1) (both from Bio X Cell, West Lebanon, NH, USA), at a dosage of 10 μg/g bodyweight for each injection, and at six different time points for the four groups. For CT mice, the mock antibody matching with the anti-platelet antibody was first injected on the day for the induction of endometriosis (day 0), and then every 5 days consecutively, with the last injection being given on day 30, and the mock antibody matching with PC61 was injected at 3 days before, 3 days after the induction of endometriosis, and then every 7 days consecutively, with the last injection being given on day 32. For the JD mice, the anti-platelet antibody was given at all seven time points that were identical to the CT group; PC61 was given at all six time points that were identical to the CT group. For the PD or TD group, anti-platelet antibody or PC61, and the mock antibody for PC61 or anti-platelet antibody were injected at the time points identical to the CT group. Our pilot experiment using flow cytometry showed that, while the isotype IgG group had an average of 12.84% of CD25+ cells in CD4+ cells, the same percentage reached a low level of 0.86% (a reduction of 93.3%) at Day 3 after injection of PC61, and remained below 1% (over 92.2% reduction) at Day 10. The trend was very similar in the percentage of FOXP3+ cells in CD4+ cells, reducing the percentage from 6.04% on Day 0 of injection to 0.64% (a reduction of 89.4%) on Day 3 after injection and remained below 1% (over 83.4% reduction) on Day 10 (data not shown). In light of this result and to ensure a low level of Tregs in blood, we injected PC61 first at 3 days before the induction of endometriosis, and then at a 7-day interval after the induction. All mice were sacrificed 35 days after induction. Before the induction of endometriosis and before sacrifice, the body weight was measured and the hotplate test was administered to all mice.

Hotplate Test Procedure and Lesion Measurement

Given that women with endometriosis and rodents with induced endometriosis exhibit central sensitization, and since mice are not vocal about their pain severity, we measured the hotplate latency of mice as a proxy. A commercially available Hot Plate Analgesia Meter (Model BME-480, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences, Tianjin, China) was used to perform the hotplate test, as reported previously (37, 38).

The endometriotic lesions were carefully excised and weighed and then fixed for immunohistochemistry (IHC) analysis or Masson Trichrome Staining. The dry weight of lesions was determined as previously reported (39).

Immunohistochemistry

Tissue samples were fixed with 4% paraformaldehyde (w/v) and embedded with paraffin. Serial sections of 4 μm were obtained from each block, with one slide being stained for hematoxylin and eosin to confirm the pathological diagnosis, and the other slides stained for TGF-β1, glycprotein A repetitions predominant (GARP), vimentin, E-cadherin, α-smooth muscle actin (α-SMA), collagen-I, FOXP3, GATA-binding protein 3 (GATA-3), T-box expressed in T cells (T-bet), RAR-related orphan receptor gamma T (RORγT), CD68, CD163, inducible nitric oxide synthase (iNOS), CD41, p-Smad3, p-PDGFR-β, p-Akt, and PDGF-BB. For positive controls, human liver tissue samples were used for staining of TSLP following the product instruction; mouse spleen tissue samples were used for staining of PDGF-BB (40), FOXP3 (41), T-bet (42), GATA-3, and RORγT (43), and for p-PDGFR-β following the product
instruction. CD163, iNOS, CD41, and α-SMA are known to be expressed in mouse endometriotic lesions (8), hence their staining in mouse endometriosis tissue samples were served as positive control in themselves. Human breast cancer tissue samples were used for staining of GARP (44), ovarian endometrioma tissue samples were used for CD68 (45), p-Smad3 (9), and p-Akt (46), deep endometriosis tissue samples were used for TGF-β1, normal endometrium tissue samples were used for E-cadherin (9), and human adenomyosis tissue samples were used for vimentin (47). For negative controls, tissue samples were incubated with rabbit serum (for p-PDGFR-β, p-Akt, TSLP, PDGF-BB, T-bet, GATA-3, RORγT, CD163, GARP, FOXP3, vimentin, α-SMA, iNOS, CD41, TGF-β1, p-Smad3) or mouse serum (for CD68, E-cadherin) instead of primary antibodies.

Routine deparaffinization and rehydration procedures were performed. For antigen retrieval, the slides were heated at 98°C for 20 min in an EDTA buffer (pH 8.0; Shanghai Sun BioTech Co, Shanghai, China) for staining of T-bet, GATA-3, RORγT, CD163, p-Smad3, p-PDGFR-β, and p-Akt; or for 30 min in citrate buffer (pH 6.0) for staining of GARP, FOXP3, CD68, iNOS, CD41, α-SMA, vimentin, E-cadherin, PDGF-BB, and TSLP, and then cooled naturally to room temperature. Table 1 lists the names, along with catalog numbers, of the primary antibodies used in this study and their respective diluted concentrations.

The slides were incubated with the primary antibodies overnight at 4°C. The next day, slides were incubated with horseradish peroxidase (HRP) labeled secondary antibody detection reagent (Sunpoly-HII; BioSun Technology Co.,
Masson Trichrome Staining

Masson Trichrome staining was used for the detection of collagen fibers in tissue samples. Tissue slides were deparaffinized in xylene and rehydrated in a graded alcohol series and then immersed in the Bouin solution, which was made with 75 ml of saturated picric acid, 25 ml of 10% formalin (w/v) solution, and 5 ml of acetic acid, at 37°C for 2 h. Tissue slides were stained with the Masson Trichrome Staining Kit (Bao, Wuhan, China) following the manufacturer’s instructions. The areas of the blue-stained collagen fiber layer in proportion to the entire field of the ectopic implants were calculated by the Image Pro-Plus 6.0.

Statistical Analysis

The comparison of distributions of continuous variables between or among two or more groups was made with the Wilcoxon’s test or Kruskal’s test, respectively. Pearson’s or Spearman’s rank correlation coefficient was used for evaluating correlations between two variables when at least one is ordinal or when both were continuous. To use data structurally and more efficiently, multiple linear regression was used to evaluate the effect of platelet and/or Tregs depletion and duration of induction on IHC parameters, or bodyweight or hotplate latency. P values < 0.05 were considered statistically significant. All computations were made with R 4.0.2 (www.r-project.org).

RESULTS

Depletion of Platelets Retards the Progression of Endometriosis

We first investigated the effect of platelet depletion on the development and fibrogenesis of endometriosis in mice based on a serial experimentation. Starting 2 days before induction, the platelet-depleting antibody was injected every 5 days during the development of endometriosis to ensure that platelets were kept to a minimum while the control mice received injection of an isotype-matched (mock) antibody (Figure 1A). The identical platelet depletion procedure was found to yield a reduction of platelets by 89.0% (5). Seven mice each from IC (isotype control) and PD (platelet depletion) groups were sacrificed at 1 and 2 weeks after induction, and then 10 mice each were sacrificed from the two groups 5 weeks after induction (Figure 1A). One mouse in the PD 1-week group died of internal bleeding at 1 week after induction.

No differences were detected in bodyweight between the two groups before, and 1, 2, and 5 weeks after the induction of endometriosis (all p-values ≥ 0.10; Figure 1B). Multiple linear regression incorporating the time of measurement and group identity (PD vs. IC) indicated that there is no difference between the two groups, but the bodyweight progressively increased over time (p < 2.2 × 10^-16, R^2 = 0.82).

We found that platelet depletion resulted in nearly significantly reduced lesion weight at 1 and 2 weeks after induction but significantly at 5th week (p = 0.051, p = 0.053, and p = 0.017, respectively; Figure 1C). However, multiple linear regression incorporating the time of measurement and group identity (PD vs. IC) indicated that PD was indeed associated with significantly lower lesion weight (p = 1.2 × 10^-5) while longer duration of induction was associated with significantly increased lesion weight (p = 4.3 × 10^-9, R^2 = 0.61; Figure 1C).

As expected, there was no significant difference in baseline hotplate latency between the two groups (p = 0.88; Figure 1C). While the PD mice had slightly decreased latency 1 and 2 weeks after the induction, the latency in IC mice appeared to decrease more rapidly, and this trend appeared to continue as time elapsed (Figure 1D). However, no significant difference in latency between the two groups was found at 1 and 2 weeks (p = 0.28 and p = 0.12, respectively; Figure 1C). Five weeks after the induction, the...
Platelet Depletion Disrupts a Predominantly Type 2 Immunity in Lesional Microenvironment and Stalls Lesional Fibrogenesis

We next performed immunohistochemistry analyses for markers of platelets (CD41+), macrophages (CD68+), M1 (iNOS+), and M2 (CD163+) macrophages as well as TSLP staining for endometriotic lesions.

CD41 staining was seen in the membrane of platelets. CD68 staining was seen in the membrane of macrophages, while CD163 staining was seen in the membrane and cytoplasm of putative M2 macrophages. The staining of iNOS was seen in the cytoplasm of putative M1 macrophages and endometriotic epithelial cells, but the latter could be distinguished by cell morphology. As such, iNOS+ epithelial cells were not included in the counting, and the scoring was done only for macrophages. Also, TSLP staining was detected diffusely in the stromal area and the epithelial cells of endometriotic lesions.

We found that the density of activated platelets was progressively increased in endometriotic lesions in IC mice (Figure 2A; Table 2). In addition, the density of macrophages (CD68+) and M2 macrophages (CD163+) was both elevated as endometriotic lesions progressed (Figure 2 and Table 2). In contrast, PD resulted in a significantly lower density of platelets, macrophages, and M2 macrophages (Figure 2 and Table 2). Interestingly, the density of M1 macrophages (iNOS+) did not change much during the entire period of lesional development, nor was there any significant difference between the two groups of mice (all p-values ≥ 0.63; Figure 2 and Table 2). Consistent with these changes, the overall lesional staining of TSLP increased slightly but significantly increased during the entire experimental period (p = 0.049), but was significantly reduced in mice with PD (p = 1.6 × 10⁻⁵, R² = 0.38; Figure 2 and Table 2). These results indicate that platelets can promote the aggregation of M2 macrophages in lesions and M2 macrophages may facilitate the progression of endometriosis.

We further stained markers of Tregs, Th1, Th2, and Th17, and GARP, and quantified the extent of lesional fibrosis by Masson trichrome staining. FOXP3, T-bet, GATA-3, and RORγT were stained positive in the nuclei of Tregs, Th1, Th2, and Th17, respectively. GARP is a transmembrane protein retained at the surface of Tregs and a few other cell types (44, 49), and is involved in TGF-β1 activation by Tregs (50, 51). GARP staining was seen in the membrane of activated platelets, Tregs, and epithelial cells of endometriotic lesions (Figure 3A).

We found that, as lesions progressed, the density of both Tregs and Th2 cells increased precipitously, but that of Th1 cells remained mostly unchanged (Figure 3 and Table 2). However, platelet depletion resulted in significantly reduced density of Tregs and Th2 cells while progressively increased the density of Th1 cells in lesions (Figure 3 and Table 2). In fact, while the density of Tregs in 5-week old lesions from IC mice was significantly higher than that in 1-week old ones (p = 0.0002), no such significant difference in PD lesions was seen (p = 0.25; Figure 3). Conversely, while the density of Th1 cells in 5-week old lesions from IC mice was essentially unchanged as compared with that in 1-week old ones (p = 0.73), in PD mice the density in 5-week old lesions was significantly higher than that in 1-week old ones (p = 0.0014; Figure 3).

In contrast to the increasing density of Tregs and Th2 cells and also to somewhat constantly low density of Th1 cells in IC mice, the density of Th17 cells (RORγT+) appeared to be relatively unchanged as lesions progressed, but at higher levels (Figure 3). The density also appeared to be relatively constant in PD mice, but it was significantly lower than that of IC mice (Figure 3 and Table 2). In fact, the density of Th17 cells in 5-week old lesions from both IC and PD mice was similar to that in 1-week old ones (p = 0.74 and p = 1.0, respectively; Figure 3 and Table 2).

Consistently, the lesional staining of GARP in IC mice increased progressively as lesions aged, but PD significantly reduced the density (Figure 3 and Table 2). In addition, the extent of lesional fibrosis also increased progressively, but PD significantly lowered it (Figure 3 and Table 2).

Taken together, we can conclude that platelets promoted the increasing aggregation of Tregs and Th2 cells as well as M2 macrophages along with a constant low-level aggregation of Th1 cells during the progression of endometriosis, which facilitated the expression of TSLP and GARP and likely induced TGF-β1 activation, resulting in lesional progression and fibrogenesis. Platelet depletion, however, facilitated the aggregation of Th1 cells while suppressed the aggregation of Tregs, Th2, and Th17 cells as well as M2 macrophages, yielding retarded lesional progression and stalled lesional fibrogenesis.

The extent of lesional fibrosis was positively correlated with the lesion weight, the density of platelets, infiltrating macrophages, M2 macrophages, Tregs, Th2 and Th17 cells, and lesional staining levels of TSLP and GARP, but negatively with the density of Th1 cells (Figure 4). Taken together, these data suggest that through promoting a predominantly type 2 immunity in lesions, promoting the aggregation of Tregs, Th2 cells, and M2 macrophages but keeping a low-level of Th1 cell aggregation in endometriotic lesions and possibly activating the TGF-β1/Smad3 signaling pathway, the platelets promote lesional fibrogenesis in endometriosis.

Depletion of Platelets and/or Tregs Retards the Progression of Endometriosis

In view of the findings from Experiment 1 that platelet depletion retarded the progression of endometriosis possibly through the disruption of the type 2 immunity in lesional microenvironment, we next carried out Experiment 2 to further explore the possible interactions between platelets and Tregs in the progression and fibrogenesis of endometriosis (Figure 5A). Thirty-two Balb/c mice were randomly divided into four groups: the PD group,
FIGURE 2 | Platelets, macrophages, and TSLP expression in endometriotic lesions of the two groups of mice in Experiment 1. (A) Representative immunohistochemical staining of CD41, CD68, CD163, iNOS, and TSLP staining in the two groups. All magnifications were ×400. Scale bar = 50 µm. (B) Kinetic changes in the density of CD41+ (platelet), CD68+ (macrophage), CD163+ (M2), and iNOS+ (M1) cells, and the staining level of TSLP. The values show the means ± SDs. 0.05 < * < 0.1; **p < 0.01; ***p < 0.001; NS, not statistically significant (p > 0.05) for the difference between the testing group and the Control group (by Wilcoxon’s test). n = 7 for each group in 1 and 2 weeks; n = 10 for each group in 5 weeks. One mouse in the PD group died of internal bleeding at 1 week after induction. IC, isotype control; PD, platelet depletion; TSLP, thymic stromal lymphopoietin.
which was injected with platelet depletion antibody; the TD group, which was injected with Tregs depletion antibody; the JD group, which was injected with antibodies for both platelet and Tregs depletion (joint depletion); and, finally, the CT group, which was injected with isotype mock antibody. Five weeks after the induction of endometriosis, all mice were sacrificed (Figure 5A). In our pilot experiment using flow cytometry, we found that the percentage of CD25+ cells in CD4+ cells was reduced by 93.3% at Day 3 after injection of PC61 and the reduction remained to be over 92.2% at Day 10 after. The trend was very similar in the percentage of FOXP3+ cells in CD4+ cells, yielding a reduction from 6.04% on Day 0 of injection to 0.64% (a reduction of 89.4%) on Day 3 after injection and remained below 1% (over 83.4% reduction) on Day 3 after injection of PC61 and the reduction remained to be over 92.2% at Day 10 after. The trend was very similar in the percentage of FOXP3+ cells in CD4+ cells, yielding a reduction from 6.04% on Day 0 of injection to 0.64% (a reduction of 89.4%) on Day 3 after injection and remained below 1% (over 83.4% reduction) on Day 10 (data not shown).

In light of this result and to ensure a low level of Tregs in blood, we injected PC61 first at 3 days before the induction of endometriosis, and then at a 7-day interval after the induction. During the whole experiment, no mice died.

While no difference in bodyweight was found at the beginning of the experiment (p = 0.33), at the end of the experiment there was a significant difference among the four groups of mice (p = 0.023; Figure 5B). Multiple linear regression incorporating the time of measurement, whether received platelet depletion, or Tregs depletion indicated that the bodyweight overall was progressively increased over time (p = 5.2 $\times$ 10^{-16} and platelet, but not Tregs, depletion resulted in reduced bodyweight (p = 0.048; $R^2$ = 0.67; Figure 5B). The reduced bodyweight might be due to possible internal bleeding because of platelet depletion.

Compared with the CT mice, the lesion weight in PD, TD, and JD groups was reduced, on average, by 64.8, 60.5, and 71.0%, respectively (all p-values $\leq$ 0.036; Figure 5C). Multiple linear regression incorporating the dummy variables indicating as whether the mouse received platelet depletion or Tregs depletion indicated that platelet depletion and Tregs depletion significantly reduced the lesion weight (p = 0.0013, and p = 0.0023, respectively), but the joint depletion did not further reduce the lesion weight (p = 0.043; $R^2$ = 0.42; Figure 5C).

While there was no difference in hotplate latency at the baseline among the four groups (p = 0.23), by the end of experiment there was a significant difference in latency among them (p = 0.0058; Figure 5D). Multiple linear regression incorporating the time of measurement, and the dummy variables indicating as whether received platelet depletion, or Tregs depletion indicated that while the time elapsed since induction significantly reduced the latency (p < 2.2 $\times$ 10^{-16}), both platelet depletion and Tregs depletion significantly prolonged the latency (p = 0.017, and p = 0.0026, respectively; $R^2$ = 0.74; Figure 5D).

### Platelets and/or Tregs Depletion Results in Reduced Aggregation of Immune Cells Suggestive of Type 2 Immunity in Endometriotic Lesions and Stalled Lesional Progression and Fibrogenesis

We then evaluated the density of platelets (CD41+), macrophages (CD68+), M2 (CD163+) and M1 (iNOS+) macrophages, Tregs (FOXP3+), Th1 (T-bet+), Th2 (GATA3+), and Th17 (RORyT+) along with TSLP staining in endometriotic lesions by IHC (Figure 6A). As expected, the lesional platelet density was significantly reduced in PD and JD mice as compared with the CT group (both p-values = 0.0013; Figure 6B, Table 3), so was in TD mice (p = 0.006). PD and JD mice also had significantly reduced macrophage density in lesions (p = 0.024 and p = 0.012, respectively; Figure 6B, Table 3), but not in TD mice (p = 0.10). While all treatment groups of mice had significantly reduced the lesional density of M2 macrophages (p = 0.0011, p = 0.028, and p = 0.0019, respectively; Figure 6B, Table 3), only the JD mice had significantly elevated density of M1 macrophages (p = 0.038; Figure 6B, Table 3). In JD mice, the density of platelets and M2 macrophages was further reduced as compared with TD mice (both p-values $\leq$ 0.038; Figure 6B, Table 3). In JD mice, the density of M1 macrophages did not change significantly compared with the TD group (p = 0.052; Figure 6B, Table 3), suggesting that platelets and Tregs may have an additive effect on the promotion of M2 dominance over M1 in endometriotic lesions.

Platelet depletion, but not Tregs depletion alone, significantly reduced the lesional staining levels of TSLP (p = 0.021, and p = 0.0047, respectively; Figure 6B, Table 3). This suggests that platelets and Tregs promoted, first, the aggregation of Tregs as well as Th2 and Th17 cells, but suppressed the aggregation of Th1 cells in endometriotic lesions.

In the three treatment groups, the lesional density of Tregs, Th2, and Th1 was significantly lower, and the density of Th1 was significantly higher, than the CT group (all p-values $\leq$ 0.046; Figure 6B, Table 3). This suggests that both platelets and Tregs promoted, first, the aggregation of Tregs as well as Th2 and Th17 cells, but suppressed the aggregation of Th1 cells in endometriotic lesions. Of particular interest, the density of Tregs in the JD mice was significantly lower than that of PD and TD mice (both p-values $\leq$ 0.030; Figure 6B, Table 3), suggesting that platelet depletion further facilitated the reduction in Tregs density in lesions. The density of Th1 in the JD mice was significantly higher than either PD or TD.
Figure 3 | The distribution of T cells, GARP staining, and Masson trichrome staining in endometriotic lesions of the two groups of mice in Experiment 1. (A) Representative immunohistochemical staining of FOXP3, T-bet, GATA-3, RORγT, GARP, along with Masson trichrome staining in the two groups. All magnifications were ×400. Scale bar = 50 µm. (B) Kinetic changes in the density of FOXP3+ (Treg), T-bet+ (Th1), GATA-3+ (Th2), and RORγT+ (Th17) cells, the staining level of GARP, and the percentage of fibrotic content in the two groups. The values show the means ± SDs. *p < 0.05; **p < 0.01; ***p < 0.001; NS, not statistically significant (p > 0.05) for the difference between the testing group and the Control group (by Wilcoxon's test). n = 7 for each group in 1 and 2 weeks; n = 10 for each group in 5 weeks. One mouse in the PD group died of internal bleeding at 1 week after induction. IC, isotype control; PD, platelet depletion; GARP, glycoprotein A repetitions predominant.
FIGURE 4 | Correlation between lesion weight, or immunohistochemistry staining and fibrotic proportion of endometriotic lesions in the two groups of mice in Experiment 1. Scatter plots showing the relationship between the extent of lesional fibrosis and the lesion weight (A), the density of platelets (B), macrophages (C), M2 macrophages (D), Tregs (E), Th1 cells (F), Th2 cells (G), and Th17 cells (H), or the staining levels of TSLP (I) and GARP (J). Each dot represents one data point from one patient. The dashed line is the regression line. The number in each figure is the Pearson correlation coefficient, followed by a symbol indicating the statistical significance level. **p < 0.01; ***p < 0.001. W, week; PD, platelet depletion; MF, macrophages; GARP, glycoprotein A repetitions predominant; TSLP, thymic stromal lymphopoietin; Sqrt, square root.
mice (both p-values $\leq 0.036$; Figure 6B, Table 3), indicating that platelets and Tregs have an additive suppressive effect on Th1 aggregation, which can also be seen from the lack of significant interaction (Table 3). When platelets and Tregs were depleted jointly, there was no significant difference in Th17 density between the JD group and the PD or TD group (both p-values $\geq 0.25$; Figure 6B, Table 3), suggesting that both platelets and Tregs facilitated Th17 aggregation via the same pathway (as seen by the positive sign of the regression coefficient, which was significant).

**Evidence for the Activation of the TGF-β1/Smad3 and PDGFR-β/PI3K/Akt Signaling Pathways by Platelets and Tregs**

Activated platelets and Tregs are known to release TGF-β1 and PDGF, two potent profibrotic cytokines (3, 52, 53). We thus set out to detect the lesional expression of TGF-β1/Smad3 and the markers of the PDGFR-β/PI3K/Akt signaling pathways by IHC. Platelets have been previously reported to activate the TGF-β1 and PDGF signaling pathways in endometriosis (3, 7). In our pilot experiment using real-time RT-PCR or Western blot, we also found that Tregs activated the TGF-β1 and PDGF signaling pathways in both endometriotic epithelial and stromal cells. The total proteins and phosphorylated forms of Smad3, PDGFR-β, and Akt were all evaluated by Western blot, but the changes were only found in the phosphorylated forms (data not shown). Consequently, we only evaluated the phosphorylated forms of these proteins in our IHC experiments. We found that TGF-β1 was stained positive mostly in the cytoplasm of ectopic endometrial epithelium and also in some stromal cells (Figure 7A). GARP staining was seen in the membrane of activated platelets, Tregs, and epithelial cells of endometriotic lesions (Figure 7A). The staining of p-Smad3 was seen prominently in the nuclei of epithelial cells and some stromal cells in the CT group, but its staining intensity was lower in the other three groups. Similarly, PDGF-BB staining was seen mostly in the cytoplasm of ectopic endometrial epithelium and also in some
stromal cells in the Control mice, but its staining intensity was lower in the other three groups (Figure 7). The staining of p-PDGFR-β was seen in the membrane of stromal cells and some epithelial cells in controls, but less intense in the three treatment groups (Figure 7A). The staining of p-Akt was observed in the nucleus of stromal cells and some epithelial cells in the CT group, but less in the other three groups (Figures 7A).

After depletion of platelets or Tregs, the staining levels of TGF-β1, GARP, p-Smad3 and PDGF-BB, p-PDGFR-β, and p-Akt were significantly lower than the CT group (all p-values ≤ 0.028; Figure 7B, Table 3). While joint or simultaneous depletion of both platelets and Tregs also resulted in the reduction of the staining levels of these markers (all p-values ≤ 0.0006; Figure 7B), the significant and positive coefficients of the interaction term on the regression (Table 3) seem to indicate that platelets and Tregs impact on these signaling pathways more or less via identical pathways. Nonetheless, JD mice had significantly lower staining levels of TGF-β1, p-Smad3, PDGF-BB, p-PDGFR-β, and p-Akt than either PD or TD mice (all p-values < 0.05; Figure 7B). Similarly, the staining levels of GARP in JD mice was significantly lower than the TD, but not PD, mice (p = 0.012 and p = 0.10, respectively; Figure 7; Table 3), suggesting that platelet and Tregs may play an additive role in the activation of these two signaling pathways in endometriosis.

Due to the profibrotic propensity of both TGF-β1 and PDGF, we next evaluated the staining of markers of EMT and FMT by IHC, and the extent of lesional fibrosis by Masson trichrome staining. E-cadherin was mainly expressed in the cytoplasm and membrane of glandular epithelial cells, vimentin was expressed in the membrane of the stromal and some epithelial cells, and α-SMA was partially stained in the stroma of endometriotic lesions (Figure 7A). In Masson trichrome staining, the collagen fibers were stained blue (Figure 7A). Again, both PD and TD significantly elevated the staining levels of E-cadherin but significantly reduced staining levels of vimentin and α-SMA as well as the proportion of collagen fibers (all p-values ≤ 0.038; Figure 7B, Table 3), suggesting that depletion of either platelets or Tregs significantly suppressed the progression of EMT and FMT. The staining levels of E-cadherin in JD mice was significantly higher than the TD, but not PD, mice (p = 0.001, and p = 0.36, respectively; Figure 7, Table 3), while the staining levels of vimentin and α-SMA in JD mice was significantly lower...
Cells (macrophages, Tregs, Th17, and Th2 cells, but negatively 
edepletion. Regardless, JD mice had signi
fucates further arrest EMT and FMT after Tregs 
Figure 7B 
symbol 
three such symbols indicate that the p-value is <0.05, 0.01, and 0.001, respectively. The 
indicates the statistical signi
fi
Figure 7B 
TABLE 3 | Results of multiple linear regression analysis of immunohistochemistry 

| Marker       | Effect of platelet depletion | Effect of Tregs depletion | Effect of Joint platelet and Tregs depletion | R²  |
|--------------|-----------------------------|--------------------------|---------------------------------------------|-----|
| CD41+ platelets |                 |                          |                                             | 0.70|
| CD68+ macrophages |      |                          |                                             | 0.30|
| CD163+ macrophages |      |                          |                                             | 0.54|
| iNOS+ macrophages |                          |                          |                                             | 0.13|
| TSLP |      |                          |                                             | 0.26|
| FOXP3+ |                          |                          |                                             | 0.77|
| Tregs |      |                          |                                             | 0.42|
| T-bet+ Th1 cells |      |                          |                                             | 0.41|
| GATA-3+ |                          |                          |                                             | 0.54|
| Th2 cells |                          |                          |                                             | 0.70|
| RORγT+ |                          |                          |                                             | 0.51|
| Th17 cells |                          |                          |                                             | 0.83|
| TGF-β1 |                          |                          |                                             | 0.74|
| GARP |                          |                          |                                             | 0.73|
| p-Smad3 |                          |                          |                                             | 0.77|
| p-PDGFR-β |                          |                          |                                             | 0.52|
| PDGF-BB |                          |                          |                                             | 0.47|
| p-Akt |                          |                          |                                             | 0.67|
| E-cadherin |                          |                          |                                             | 0.76|
| Vimentin |                          |                          |                                             | 0.09|
| α-SMA |                          |                          |                                             | 0.13|
| Extent of lesional fibrosis |                          |                          |                                             | 0.26|

The symbol "↓" denotes elevation while "↑" denotes reduction. The number of "↑" or "↓" indicates the statistical significance level associated with variable, in which one, two, and three such symbols indicate that the p-value is <0.05, 0.01, and 0.001, respectively. The symbol "—" means no association.

than that the TD, but not PD, mice (both p-values ≤0.040, and both p-values >0.29; Figure 7, Table 3), suggesting that platelet depletion could further arrest EMT and FMT after Tregs depletion. Regardless, JD mice had significantly lower extent of lesional fibrosis than either PD or TD mice (both p-values <0.05; Figure 7B).

The extent of lesional fibrosis was positively correlated with the lesion weight, the density of platelets, macrophages, M2 macrophages, Tregs, Th17, and Th2 cells, but negatively correlated with the hotplate latency and the density of Th1 cells (Table 4). In addition, it correlated positively with the lesional staining levels of markers of the TGF-β and PDGF signaling pathways, such as TGF-β1, GARP, p-Smad3, PDGF-BB, p-PDGFR-β, and p-Akt, as well as the staining levels of TSLP. As expected, it correlated negatively with the staining levels of E-cadherin but correlated positively with lesional staining levels of vimentin and α-SMA (Table 4). Multiple linear regression incorporating lesion weight, platelet density, macrophage density, M2 macrophage density, Tregs density, Th2 and Th17 cell density, TGF-β1, p-Smad3, PDGF-BB, p-PDGFR-β, p-Akt, E-cadherin, vimentin, and α-SMA as covariates indicated that E-cadherin staining was negatively associated, while macrophage density, Tregs density, and p-Akt staining were positively associated, with the extent of lesional fibrosis (all p-values <0.011, R² = 0.94).

We also carried out a linear regression analysis of TGF-β1 staining levels using lesion weight, and densities of platelets, macrophages, M2 macrophages, Tregs, Th2, and Th17 cells as covariables. We found that the platelet density and Tregs density in lesions were the only two variables that are correlated positively with TGF-β1 staining levels (both p-values <3.2 × 10⁻³, R² = 0.83). Similarly, linear regression analysis of PDGF-BB staining levels on the same set of covariables identified lesion weight and platelet density as the two variables that are positively associated with the staining levels (both p-values <0.004, R² = 0.88).

**DISCUSSION**

Through two mouse experiments, we have shown that, by disrupting predominantly a type 2 immune response in lesional microenvironment, both platelets and Tregs depletion decelerated lesional progression and fibrogenesis, likely through the suppression of the TGF-β1/Smad3 and PDGFR-β/Pi3K/Akt signaling pathways. In particular, platelet depletion resulted in significantly reduced lesional expression of TSLP, leading to reduced aggregation of macrophages and M2 macrophages, and of Tregs, Th2, and Th17 cells but an increased aggregation of Th1 cells, in lesions, which, in turn, yields retarded fibrogenesis. Similarly, Tregs depletion resulted in suppression of platelet aggregation, and reduced aggregation of M2 macrophages, Th2, and Th17 cells but increased aggregation of Th1 cells, in lesions. In addition, both platelet and Tregs depletion resulted in depressed TGF-β1/Smad3 and PDGFR-β/Pi3K/Akt signaling, leading to arrested EMT, FMT, and fibrogenesis. Taken together, our study highlights the critical roles of immune cells in general and platelets and Tregs in particular in lesional development and fibrogenesis, and suggests that the type 2 immunity may play a vital role in lesional fibrogenesis. In addition, our study provides more credence to the ReTIAR notion, since, through the ReTIAR lens, we can coherently piece together seemingly unrelated findings, such as TSLP overexpression, M2 macrophages, platelet aggregation, and the Th1/Th2imbalance in endometriosis.

Our results are consistent with the burgeoning and overwhelming data in support of a predominantly type 2 immunity in lesional microenvironment (18, 20, 21, 54). Indeed, levels of Th2 cytokines, such as IL-4 (55–57), IL-13 (58), IL-25 (59), and IL-33 (60–63), in lesions or the peritoneal fluid from women with endometriosis have been reported to be elevated. IL-4 can stimulate the proliferation of endometriotic stromal cells (57), and, in conjunction with PGE2, may enhance estrogen production in endometriotic tissues (64). IL-33 treated mice with induced endometriosis are highly vascu

---

Table 4

| Marker | R²  |
|--------|-----|
| TSLP | 0.52|
| PDGF-BB | 0.47|
| p-Akt | 0.67|
| E-cadherin | 0.76|

...
are in broad agreement with a preponderance of published data indicating more Tregs infiltration in endometriotic lesions (68, 69), especially in deep endometriotic lesions (70). They also are in line with the reported higher concentrations of IL-17 in peritoneal fluid or plasma from women with endometriosis (71–73), which is found to trigger proinflammatory cytokines and angiogenic growth factors (73). In particular, they are consistent with the increase in Tregs, Th2, and Th17 cells in endometriosis (20, 74–76). Tregs secreted fibrinogen-like protein 2 (FGL-2) can promote the production of Th2 cytokines, with concomitant inhibition of Th1- and Th17-oriented immunity (77). Tregs could also induce human monocytes to differentiate into M2-like macrophages (74).

Our study is also consistent with our previous report that endometriotic lesions exhibited progressive cellular changes consistent with the progressive EMT, FMT, SMM, and fibrogenesis, while antiplatelet treatment resulted in significant hindrance to EMT, FMT, SMM, and fibrogenesis and reduced lesion weight (34). Platelet granules contain a variety of cellular
growth factors and cytokines (78, 79), such as TGF-β1, PDGF, and vascular endothelial growth factor (VEGF), that may accelerate lesional development and fibrogenesis (80). In particular, activated platelets can release TGF-β1 and induce the TGF-β1/Smad signaling pathway, promoting EMT, FMT, and SMM in lesions, resulting ultimately in fibrosis (3).

TSLP is known to promote the differentiation of naïve T cells into a Th2 phenotype, a type 2 immune response, and the secretion of various profibrotic factors in DCs dependent or independent manner (16, 26, 32, 33, 81–83). Incidentally or not, DCs have been reported to be significantly increased in peritoneal endometriotic lesions (84), which may promote angiogenesis and lesion growth in endometriosis (85). Plasmacytoid DCs are reported to facilitate endometriosis development through angiogenesis during the early disease stage by secreting IL-10 (86). TSLP induces cytokine production by human ILC2s, reinforces GATA3 expression, and therefore helps to sustain the type 2 immunity (95). So why the type 1 immunity, which is characterized by inflammation, can be a hindrance to lesional progression and fibrogenesis while the type 2 immunity can be a promoter?

First of all, after each cyclic bleeding, endometriotic epithelial and stromal cells may secrete alarmins such as IL-25, IL-33, and TSLP (96). In fact, endometriotic stromal cells themselves can secrete platelet-activating molecules (94). Activated platelets can induce estrogen production in endometriotic stromal cells (97, 98), which, in turn, may induce TSLP secretion (30). Through activation of DCs, TSLP can promote Th2 cell differentiation and propagate a type 2 immune response (16). Similarly, IL-33, which is in high concentration in endometriosis (60, 61, 63, 99), can also induce a Th2 response on mast cells and Th2 cells (16). Th2 cell-derived IL-4 and IL-13 can alternatively activate macrophages (100) and suppress Th1 cells, resulting in increased Th2 cytokine production. Th2 cells, along with M2 macrophages, eosinophils, basophils, and ILC2s, promote the type 2 immunity-induced fibrogenesis (16). This seems to occur exactly in endometriosis (62, 99).

Second, IFN-γ secreted by Th1 cells mediates the activation of classical or M1 macrophages (101–103), which express Th1 and Th17-polarizing cytokines IL-12, IL-23, IL-27, and Th1-requiring chemokines CXCL9, CXCL10, and CXCL11. In contrast, M2 macrophages support the resolution of inflammation by the expression of anti-inflammatory molecules such as IL-10, TGF-β, and IL-1Ra (104). M2 macrophages can also recruit Th2 and Tregs through secretion of the CCL17 and CCL1 chemokines (105). Th1 cells and M1 macrophages are mutually promotional, so are Th2 cells and M2 macrophages (104). Hence, the presence of Th2 cytokines would further promote the lesional dominance of a type 2 immunity.

Both IL-12 and IFN-γ can induce the differentiation of naïve CD4 cells to Th1 cells to produce the pro-inflammatory cytokine IFN-γ (106), which reduces collagen production and fibronectin expression (107, 108). In contrast, Th2 cytokine IL-4 increases collagen production (108). This may explain as why IL-12 inhibits lesional development (36, 65), so do IFN-γ and IL-2 (21).

Third, Th17 cells that express the pro-inflammatory cytokine IL-17A is an important driver of fibrosis. IL-17A expression has depletion, the density of Tregs in endometriotic lesions remained at a low level 1, 2, and 5 weeks after the induction of endometriosis, which was significantly lower than that in Control mice. This suggests that platelets can promote the proliferation or recruitment of Tregs in endometriosis, possibly through the secretion of TGF-β1 and the up-regulation of TSLP expression in endometriotic lesions. Endometriotic stromal cells themselves can also secrete platelet-activating molecules (94). In addition, our study showed that Tregs depletion resulted in smaller lesions, which may consequently either reduce the amount of platelet-activating molecules secreted by endometriotic cells or lead to a reduced number of potentially activatable platelets due to smaller lesions. In either case, this would yield the net effect of decreased platelet activation.

Endometriosis is often said to have enigmatic pathogenesis and pathophysiology. It has been traditionally viewed as an estrogen-dependent disease, as well as an inflammatory condition (95). So why the type 1 immunity, which is characterized by inflammation, can be a hindrance to lesional progression and fibrogenesis while the type 2 immunity can be a promoter?
been implicated in the pathogenesis of pulmonary fibrosis, chronic allograft rejection, fibrosis in orthotopic lung transplantation, myocardial fibrosis, and hepatitis-induced hepatic fibrosis (109, 110).

Fourth, Tregs also participate in tissue repair, mainly through macrophage polarization, since they secrete IL-10, IL-4, and IL-13, which induces the transition to M2 macrophages (111). M2 macrophages reduce the inflammatory cytokine secretion, and their activity is converted into regenerative activity, which is critical for tissue repair (101, 112, 113).

We summarize this line of reasoning in Figure 8. We note that many seemingly isolated findings can be organically and coherently integrated into this ReTIAR framework, which is essentially a sketch of a roadmap for future studies. This is important, since without a roadmap, we can only see the tree leaves or branches, or at most isolated trees, but not the forest. We can only grope, akin to blind men trying to figure out what an elephant looks like. Indeed, with this roadmap, perhaps we can also investigate other suspected players, such as ILC2s, IL-25, TSLP, DCs, eosinophils, and basophils in the future.

This roadmap also has important clinical implications as well. For example, we can now understand why the trial on anti-TNF- α therapy failed (114), since TNF-α is a Th1 cytokine. We can also understand why a therapy based on the recombinant IL-2, a Th1 cytokine, which was launched ostensibly based on its putative anti-inflammatory propensity, failed in endometriosis (115). This is because Tregs constitutively express high levels of CD25, an IL-2 receptor, and are easily expanded using continuous low levels of IL-2. In addition, pentoxifylline also failed in clinical trials (116), since pentoxifylline suppresses the production of TNF-α and IFN-γ while increases the production of Th2 cytokines (117). Clearly, the elucidation of the lesional immune microenvironment should guide us to choose the best therapeutics while avoid the ineffective ones.

This study has several strengths. First, by employing a serial design and by depleting platelets and/or Tregs, we have unveiled the facilitative roles of both platelets and Tregs in lesional progression and fibrogenesis. In particular, we have demonstrated the time-dependent nature of several cell types (Th1 vs. Th2 cells, for example). This time dependency may explain as why we often see conflicting reports in the literature, aside from the difference in methodology and sample sizes. Second, by embedding our experiments within the ReTIAR framework or as a backbone, which allows us to stand on the shoulders of giants who have advanced our knowledge on wound healing, we were able to see a much bigger picture on how lesions progress. This should help us and our fellow investigators to see the forest, instead of each individual leaves or trees, so that many seemingly isolated findings can be pieced together. Third, by depleting platelets and Tregs separately or jointly, our data suggested that platelets played a more active role in inducing TSLP expression, which is crucial in inducing a type 2 immunity.
and in facilitating the proliferation of Tregs. Lastly, we allowed a sufficiently long observation period after endometriosis induction to investigate the role of platelets and Tregs in fibrogenesis. Collectively, these complementary approaches provide more credible data.

This study also has several limitations. First, our study is limited by the use of histologic and immunohistochemistry analyses only. It lacks confirmation by flow cytometry on changes in the density of related immune cells in circulation after platelet or Tregs depletion, which may show the systemic immunological alterations rather than just within endometriotic lesions alone. In addition, there is a lack of molecular data that can provide a more definitive proof for the involvement of signaling pathways, or to elucidate the molecular mechanisms on how platelets and Tregs interact with each other. This should await for more research in the future. Second, to conform with the platelet depletion groups, we used the anti-CD25 antibody for Tregs depletion, instead of using the transgenic mouse expressing a diphtheria toxin receptor-GFP fusion protein under the control of the FOXP3 locus for the Tregs depletion, which should be more specific in terms of Tregs depletion (118). CD4+ Tregs can be identified by their constitutive expression of CD25. However, the existence of CD4+CD25- Tregs and the expression of CD25 in activated conventional T cells preclude the discrimination between Tregs and activated conventional T cells, which may limit the interpretation of data obtained by the use of anti-CD25-depleting antibodies (119–123). Third, we depleted platelets or Tregs but did not transfer platelets or Tregs back into the mice. Hence, in essence, we have “loss of function” data but no “gain of function” data. Of course, platelet infusion appears to accelerate fibrogenesis of endometriosis in mouse (5). Further mechanistic research is warranted in the future.

In summary, our study demonstrates that both platelet and Tregs depletion decelerated lesional progression and fibrogenesis by disrupting predominantly a type 2 immune response in lesional microenvironment. It suggests that in the course of lesional progression, platelets may induce TSLP, leading to a type 2 immune response in the lesional microenvironment, and, ultimately, to fibrosis if unimpeded. Taken together, our study highlights the critical roles of immune cells in general and platelets and Tregs in particular in lesional development and fibrogenesis, and suggests the type 2 immunity may play a vital role in lesional fibrogenesis. In addition, our study provides more credence to the ReTIAR notion, since, thorough the ReTIAR lens, we can coherently piece together seemingly isolated findings, such as TSLP overexpression, M2 macrophages, platelet aggregation, and the Th1/Th2 balance.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the Institutional Experimental Animals Review Board of Shanghai OB/GYN Hospital, Fudan University.

AUTHOR CONTRIBUTIONS

S-WG conceived the study, analyzed the data, and drafted the manuscript. FX conducted the experiments, analyzed the data, and wrote the manuscript. S-WG and XL contributed reagents, conceived the experiments, provided financial support, and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This research was supported in part by grants from the National Science Foundation of China (81530040 and 81771553 to S-WG; 81671436 and 81871144 to XL), and an Excellence in Centers of Clinical Medicine grant (2017ZZ01016) from the Science and Technology Commission of Shanghai Municipality.

ACKNOWLEDGMENTS

We would like to thank two reviewers for their constructive comments on an earlier version of this manuscript.

REFERENCES

1. El-Toukhy T. Prevalence of Endometriosis: how close are we to the truth? BJOG (2020). doi: 10.1111/1471-0528.16466
2. Guo SW. Fibrogenesis resulting from cyclic bleeding: the Holy Grail of the natural history of ectopic endometrium. Hum Reprod (2018) 33(3):353–6. doi: 10.1093/humrep/dex015.
3. Zhang Q, Duan J, Liu X, Guo SW. Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol (2016) 428:1–16. doi: 10.1016/j.mce.2016.03.015
4. Zhang Q, Duan J, Olson M, Fazleabas A, Guo SW. Cellular Changes Consistent With Epithelial-Mesenchymal Transition and Fibroblast-to-Myofibroblast Transdifferentiation in the Progression of Experimental Endometriosis in Baboons. Reprod Sci (2016) 23(10):1409–21. doi: 10.1177/193719116641763
5. Ding D, Liu X, Duan J, Guo SW. Platelets are an unindicted culprit in the development of endometriosis: clinical and experimental evidence. Hum Reprod (2015) 30(4):812–32. doi: 10.1093/humrep/dev025
6. Yan D, Liu X, Xu H, Guo SW. Mesothelial Cells Participate in Endometriosis Fibrogenesis Through Platelet-Induced Mesothelial-Mesenchymal Transition. J Clin Endocrinol Metab (2020) 105(11):1–24. doi: 10.1210/clinem/dgaa550
7. Yan D, Liu X, Xu H, Guo SW. Platelets induce endothelial-mesenchymal transition and subsequent fibrogenesis in endometriosis. Reprod BioMed Online (2020) 41(3):500–17. doi: 10.1016/j.rbmo.2020.03.020
21. Mier-Cabrera J, Gonzalez-Gallardo S, Hernandez-Guerrero C. Effect of 
2. Gieseck RL, Wilson 3MS, Wynn TA. Type 2 immunity in tissue repair and 
12. Ding D, Chen Y, Liu X, Jiang Z, Cai X, Guo SW. Diagnosing Deep 
13. Sun BK, Siprashvili Z, Khavari PA. Advances in skin grafting and treatment 
14. Boothby IC, Cohen JN, Rosenblum MD. Regulatory T cells in skin injury: At 
10. Guo SW, Groothuis PG. Is it time for a paradigm shift in drug research and 
17. Siedentopf F, Tariverdian N, Rucke M, Kentenich H, Arck PC. Immune 
15. Sharma A, Rudra D. Emerging Functions of Regulatory T Cells in Tissue 
24. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic 
25. Sims JE, Williams DE, Morrissey PJ, Garka K, Foxworth D, Price V, et al. 
26. Gieseck RL, Wilson 3MS, Wynn TA. Type 2 immunity in tissue repair and 
27. Nat Rev Immunol (2018) 18(1):162–76. doi: 10.1038/nri.2017.90 
30. Chang KK, Liu LB, Li H, Mei J, Shao J, Xie F, et al. TSLP induced by estrogen 
31. Liu X, Zhang Q, Guo SW. Histological and Immunohistochemical 
32. Honda H, Barrueto FF, Gogusev J, Im DD, Morin PJ. Serial analysis of gene 
33. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. 
34. Zhang Q, Liu X, Guo SW. Progressive development of endometriosis and its 
35. Council NR. Guide for the care and use of laboratory animals. 
36. Somigiana E, Viganò P, Rossi G, Carnellini S, Vignali M, Panina-Bordignon P. 
37. Siedentopf F, Tariverdian N, Rucke M, Kentenich H, Arck PC. Immune 
38. Li G, Jin F, Du J, He Q, Yang B, Luo P. Macrophage-secreted TSLP and 
39. Bacci M, Capobianco A, Monno A, Cottone L, Di Puppo F, Camisa B, et al. 
40. Dill RE, Miller EK, Dyer BJ, Iacopino AM. Synthesis of platelet-derived 
41. Li Y, Nie J, Liu X, Zheng Y, Guo SW, Trichostatin A. A histone deacetylase 
42. Qiao X, Xie X, Shi W, Tang J, Shao Y, Li F. OCH ameliorates bone marrow 
43. Qiao X, Xie X, Shi W, Tang J, Shao Y, Li F. OCH ameliorates bone marrow 
44. Metelli A, Wu BX, Fugle CW, Rachidi S, Sun S, Zhang Y, et al. 
45. Honda H, Barrueto FF, Gogusev J, Im DD, Morin PJ. Serial analysis of gene 
46. Honda H, Barrueto FF, Gogusev J, Im DD, Morin PJ. Serial analysis of gene 
47. Liu Y, Nie J, Liu X, Zheng Y, Guo SW, Trichostatin A. A histone deacetylase 
48. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
49. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic 
50. Duan J, Liu X, Wang H, Guo SW. The M2a macrophage subset may be 
51. Bennett LM, Maskell DC, Jones RM, Hoyland JA, Moxham J. Proteomic 
52. Metelli A, Wu BX, Fugle CW, Rachidi S, Sun S, Zhang Y, et al. 
53. Cheng XX, Liu LB, Li H, Mei J, Shao J, Xie F, et al. TSLP induced by estrogen 
54. Metelli A, Wu BX, Fugle CW, Rachidi S, Sun S, Zhang Y, et al. 
55. Guo SW, Groothuis PG. Is it time for a paradigm shift in drug research and 
56. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
57. Guo SW, Groothuis PG. Is it time for a paradigm shift in drug research and 
58. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
59. Liu Y, Nie J, Liu X, Zheng Y, Guo SW, Trichostatin A. A histone deacetylase 
60. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
61. Liu Y, Nie J, Liu X, Zheng Y, Guo SW, Trichostatin A. A histone deacetylase 
62. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
63. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
64. Liu Y, Nie J, Liu X, Zheng Y, Guo SW, Trichostatin A. A histone deacetylase 
65. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
66. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
67. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
68. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
69. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
70. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
71. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
72. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
73. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
74. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
75. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
76. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
77. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
78. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
79. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
80. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
81. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
82. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
83. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
84. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
85. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
86. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
87. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
88. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
89. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
90. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
91. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
92. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
93. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
94. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
95. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
96. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
97. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
98. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
99. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A, 
100. Solé-Casals M, Cervera E, Remón E, Barbé M, Sánchez-Nicolás J, Pellicer A,
48. Shen F, Liu X, Geng JG, Guo SW. Increased immunoreactivity to SLIT/ROBO1 in ovarian endometriomas: a likely constituent biomarker for recurrence. *Am J Pathol* (2009) 175(2):479–88. doi: 10.1016/j.ajpath.2009.09.0024

49. Vermeersch E, Deneorme F, Maes W, De Meyer SF, Vanhoorebeke K, Edwards J, et al. The role of platelet and endothelial GARP in thrombosis and hemostasis. *PloS One* (2017) 12(3):e0173329. doi: 10.1371/journal.pone.0173329

50. Lienart S, Merceron R, Vanderaa C, Lambert F, Colau D, Stocks J, et al. Structural basis of latent TGF-beta1 presentation and activation by GARP on human regulatory T cells. *Science* (2018) 362(6417):592–6. doi: 10.1126/science.aau2909

51. Stocks J, Dedobbeleer O, Lucas R. Role of GARP in the activation of latent TGF-beta1. *Mol Biol Syn* (2013) 17(10):1925–35. doi: 10.1037/cmbo2013.1

52. Lo Re S, Lecocq M, Uwambayinema F, Yakoub Y, Delos M, Demoulin JB, et al. Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T cells in ectopic endometrium and ectopic decidua. *Reprod Biol Endocrinol* (2010) 8:116. doi: 10.1186/1477-787-8-116

53. Podgaec S, Barbeiro DF, Guevoglihanian-Silva BY, Belfelli P, Abrao MS, Baracat EC. Foxp3 expression in deep resectoidosigmoid endometriosis lesions and its association with chronic pelvic pain. *J Reprod Immunol* (2014) 104:105–9. doi: 10.1016/j.jri.2014.05.002

54. Hirota Y, Osuga Y, Hamasaki K, Hasegawa A, Tajima T, et al. Peritoneal fluid concentrations of interleukin-17 correlate with the severity of endometriosis and infertility of this disorder. *BIOG* (2005) 112(4):1153–5. doi: 10.1011/j.1471-0528.2005.00639.x

55. Itoh H, Sashihara T, Hosono A, Kaminogawa S, Uchida M. Interleukin-12 increases the secretion of interleukin-17 and the expression of cyclooxygenase 2 in endometriosis. *Fertil Steril* (2008) 96(1):113–7. doi: 10.1016/j.fertnstert.2011.04.060

56. Ahn SH, Edwards AK, Singh SS, Young SL, Lessey BA, Tayade C. IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors. *J Immunol* (2015) 196(5):2591–600. doi: 10.4049/jimmunol.1501138

57. Yuan M, Li D, An M, Li Q, Zhang L, Wang G. Rediscovering peritoneal macrophages in a murine endometriosis model. *Hum Reprod* (2017) 32(9):2169–77. doi: 10.1093/humrep/dex274

58. Hudson QJ, Ashjaei K, Perricos A, Kuessel L, Husslein H, Wenzl R, et al. Endometriosis Patients Show an Increased M2 Response in the Peritoneal CD14(+low)/CD68(+) Macrophage Subpopulation Coupled with an Increase in the T-helper 2 and T-Regulatory Cells. *Reprod Sci* (2020) 27(10):1920–31. doi: 10.1007/s43032-020-00211-9

59. Gogacz M, Winkler I, Bojarska-Junak A, Tabarkiewicz J, Semczuk A, Rechberger T, et al. Increased percentage of TH17 cells in peritoneal fluid is associated with severity of endometriosis. *J Reprod Immunol* (2016) 117:39–44. doi: 10.1016/j.jri.2016.04.289

60. Wang J, Vuitton DA, Muller N, Henphill A, Spiliotis M, Blagosklonov O, et al. Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4+ CD25+ Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice. *PloS Negl Trop Dis* (2015) 9(5):e0003755. doi: 10.1371/journal.pntd.0003755

61. Holt JC, Niewiarowski S. Biochemistry of alpha granule proteins. *Semin Hematol* (1985) 22(2):151–63.

62. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. *Arterioscler Thromb Vasc Biol* (2003) 23(12):2311–7. doi: 10.1161/01.ATV.00000

63. Santulli P, Borgheze B, Chouzouneaux S, Vaiman D, Streuli I, et al. Serum and peritoneal interleukin-33 levels are elevated in deeply infiltrating endometriosis. *Hum Reprod* (2012) 27(7):2001–11. doi: 10.1093/humrep/deb154

64. Miller IE, Monsanto SP, Ahn SH, Khaliq K, Fazeblaas AT, Young SL, et al. Interleukin-33 modulates inflammation in endometriosis. *Sci Rep* (2017) 7(1):17903. doi: 10.1038/s41598-017-18224-x

65. Cao Y, Liu X, Guo SW. Plasma High Mobility Group Box 1 (HMGB1), Osteopontin (OPN), and Hyaluronic Acid (HA) as Admissible Biomarkers for Endometriosis. *Hum Reprod* (2012) 27(7):2131–9. doi: 10.1093/humrep/deb145

66. Urata Y, Osuga Y, Akiyama I, Nagai M, Isumi G, Takamura M, et al. Interleukin-4 and prostaglandin E2 synergistically up-regulate β3a-hydroxysteroid dehydrogenase type 2 in endometrioma stromal cells. *J Clin Endocrinol Metab* (2013) 98(4):1583–90. doi: 10.1210/jc.2012-2347

67. Itoh H, Sashihara T, Hosono A, Kaminogawa S, Uchida M. Interleukin-12 inhibits development of ectopic endometrial tissues in peritoneal cavity via activation of NK cells in a murine endometriosis model. *Cytootechnology* (2011) 63(2):133–41. doi: 10.1007/s10592-010-9321-x

68. Smith KA, Pearson CB, Hachez AM, Xia DL, Wachtman LM. Alternative activation of macrophages in rhesus macaques (Macaca mulatta) with endometriosis. *Comp Med* (2012) 62(4):303–10.

69. Gou Y, Li X, Li P, Zhang H, Xu T, Wang H, et al. Estrogen receptor beta upregulates CCL2 via NF-kappaB signaling in endometrial stromal cells and recruits macrophages to promote the pathogenesis of endometriosis. *Hum Reprod* (2019) 34(4):646–58. doi: 10.1093/humrep/dez019

70. Berbic M, Hey-Cunningham AJ, Ng C, Tokushige N, Ganewatta S, Markham R, et al. The role of Foxp3+ regulatory T-cells in endometriosis: a potential controlling mechanism for a complex, chronic immunological condition. *Hum Reprod* (2010) 25(4):900–7. doi: 10.1093/humrep/deq020

71. Basta P, Majka M, Jozwik J, Lesnyk E, Knafel A, Grabiec M, et al. The frequency of CD25+CD4+ and FOXP3+ regulatory T cells in endometriotic tissue is correlated with endometriosis and eutopic development. *Reprod Sci* (2019) 26(4):485–97. doi: 10.1002/pra.5339

72. Mjosberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, Blom B, et al. The transcription factor GATA3 is essential for the function of human type 2
innate lymphoid cells. *Immunity* (2012) 37(4):649–59. doi: 10.1016/j.immun.2012.08.015

88. Mollon, IAB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J, et al. Interleukin-33 and Interferon-gamma Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. *Immunity* (2015) 43(1):161–74. doi: 10.1016/j.immun.2015.05.019

89. Liu D, Guo M, Zhou P, Xiao J, Ji X. TSLP promote M2 macrophages polarization and cardiac healing after myocardial infarction. *Biochim Biophys Res Commun* (2019) 516(2):437–44. doi: 10.1016/j.bbrc.2019.06.041

90. Krasimirova E, Velikova T, Ivananova-Todorova E, Tumanglova-Yuzer K, Kalinova D, Boyadjieva V, et al. Treg/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients. *World J Exp Med* (2017) 7(3):84–96. doi: 10.5493/wjem.v7i3.84

91. Toomer KH, Malek TR. Cytokine Signaling in the Development and Homeostasis of Regulatory T Cells. *Cold Spring Harb Perspect Biol* (2018) 10(3):a028597. doi: 10.1101/cshperspect.a028597

92. Park JH, Jeong DY, Peyrin-Biroulet L, Eisenhut M, Shin JII. Insight into the role of TSPL in inflammatory bowel diseases. *Autoimmun Rev* (2017) 16(1):55–63. doi: 10.1016/j.autrev.2016.09.014

93. Lee JY, Lim YM, Park MJ, Min SY, Cho ML, Sung YC, et al. Murine thymic stromal lymphopoitin promotes the differentiation of regulatory T cells from thymic CD4(-)CD8(-)CD25(-) naive cells in a dendritic cell-independent manner. *Immunol Cell Biol* (2008) 86(2):206–13. doi: 10.1093/icb/1101027

94. Guo SW, Du Y, Liu X. Endometriosis-Derived Stromal Cells Secrete Thrombin and Thromboxane A2, Inducing Platelet Activation. *Reprod Dev Med* (2019) 3(2):69–76. doi: 10.4103/2096-2924.262390

95. Qi Q, Liu X, Zhang Q, Guo S-W. Platelets induce increased estrogen production of L-arginine metabolism. *Immunity* (2010) 32(5):593-604. doi: 10.1016/j.immuni.2010.05.007

96. Balasch J, Fabregues F, Carmona F, Martinez-Roman S, Manau D, et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized placebo-controlled trial. *Hum Reprod* (2008) 23(9):2017–23. doi: 10.1093/humrep/den177

97. Acien P, Velasco I, Acien M, Quereda F. Treatment of endometriosis with tridimensional ultrasound-guided drainage and recombinant interleukin-2 in the cysts: a third clinical trial. *Gynecol Obstet Invest* (2010) 69(3):203–11. doi: 10.1159/000270901

98. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. *J Exp Med* (2007) 204(1):57–63. doi: 10.1084/jem.20061852

99. Nakaguchi S. Naturally arising Foxp3-expressing CD25(-)CD4+ regulatory T cells in immunological tolerance to self and non-self. *Nat Immunol* (2005) 6(4):345–52. doi: 10.1038/nii1178

100. Leithauser F, Meinhardt-Krajina T, Fink K, Wotschke B, Poller P, Reimann J. Foxp3-expressing CD103+ regulatory T cells accumulate in dendritic cell aggregates of the colonic mucosa in murine transfer colitis. *Am J Pathol* (2014) 185(2):189–98. doi: 10.1016/j.amjpath.2014.05.002

101. Nordenham DJ, Lee JX, Beilharz MW. Intratumoural regulatory T cells: a potential new target in cancer immunotherapy. *Biochem Biophys Res Commun* (2006) 343(1):684–91. doi: 10.1016/j.bbrc.2006.03.018

102. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. *J Exp Med* (2001) 194(6):823–52. doi: 10.1084/jem.194.6.823

103. Roh YS, Park S, Lim CW, Kim D. Depletion of Foxp3+ Regulatory T Cells Promotes Profibrogenic M1/M2 of Cholestasis-Induced Liver Injury. *Dig Dis Sci* (2015) 60(7):2009–18. doi: 10.1007/s10620-014-3438-2

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Xiao, Liu and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in or any form is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.